Trial results comparing patient-reported outcomes for rimegepant and triptans in migraine treatment were posted on ClinicalTrials.gov on 2026-01-22. The study, conducted using data from the 2023 US National Health and Wellness Survey, included 74 participants reporting rimegepant use and 682 reporting triptan use for migraine medication.
Background
The study investigated patient-reported outcomes for rimegepant and triptans in individuals with migraine. This cross-sectional study utilized data from the 2023 US National Health and Wellness Survey (NHWS).
Trial design
The study (NCT06680206) was a completed cross-sectional study that leveraged data from the 2023 US National Health and Wellness Survey (NHWS). The NHWS is a large, nationally representative population survey (N=75,007). This specific analysis enrolled 1395 participants from the NHWS who reported on their migraine treatment. The study compared patient-reported outcomes for rimegepant and triptans in individuals with migraine.
Key results
The study reported participant counts based on migraine medication type and treatment type. For the outcome 'Number of Participants According to Migraine Medication Type (Prescription Drug or Over the Counter [OTC])', the reported participant counts were:
- Rimegepant: 74 participants
- Triptans: 682 participants
Further data for this outcome showed:
- Rimegepant: 61 participants
- Triptans: 578 participants
And for another category within this outcome:
- Rimegepant: 0 participants
- Triptans: 0 participants
For the outcome 'Number of Participants According to Migraine Treatment Type (Acute or Prevention)', the reported participant counts were:
- Rimegepant: 0 participants
- Triptans: 837 participants
Further data for this outcome showed:
- Rimegepant: 0 participants
- Triptans: 0 participants
And for another category within this outcome:
- Rimegepant: 135 participants
- Triptans: 423 participants
Statistical analyses were performed, yielding several p-values without specific outcome titles linked in the available results summary:
- A Fisher Exact test resulted in p-values of 0.928 and 0.001.
- A t-test, 2-sided, resulted in a p-value of 0.895.
- Chi-squared analyses resulted in p-values of 0.463 (for '1 drug class' and '2 or more drug classes') and 0.644 (for '3 or more drug classes').
What this means
The results of this cross-sectional survey provide insight into the self-reported usage patterns of rimegepant and triptans among individuals with migraine in the US. The reported participant counts indicate that a substantially larger number of survey respondents reported using triptans compared to rimegepant across several medication and treatment type categories. While statistical analyses were conducted, the specific implications of the reported p-values for 0.001, 0.928, 0.895, 0.463, and 0.644 regarding comparative effectiveness or patient outcomes are not detailed in the available results.
Source
The information for these trial results was sourced from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT06680206, titled 'Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey,' were posted on 2026-01-22 on clinicaltrials.gov.